Bright Minds Biosciences Announces Non-Executive Director Appointment

Bright Minds Biosciences Inc. (CSE:DRUG | NASDAQ:DRUG) a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the appointment to its board of directors of David Weiner, MD, as a non-executive director. The appointment is effective immediately.

“It is an honor to join the Bright Minds Board as the Company transitions from a discovery to a development organization. I am eager to share my perspectives and experience to help Bright Minds progress its innovative clinical and preclinical drug discovery programs,” stated David Weiner, MD.

Dr. Weiner has over 25 years of experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare diseases. He began his career at ACADIA Pharmaceuticals, where he held a series of discovery research and clinical development roles working on multiple central nervous system (CNS) therapeutics, most notably pimavanserin, a 5-HT_2A receptor inverse agonist, which is approved for the treatment of Parkinson’s disease psychosis. Dr. Weiner also served as the Chief Medical Officer (CMO) and Interim Chief Executive Officer (CEO) for Proteostasis Therapeutics, CMO at aTyr Pharma and Lumos Pharma, CEO at Amathus Therapeutics, and as an independent board member and senior executive at Eleusis, a company focused on therapeutic development of psychedelics and novel 5-HT_2A receptor agonists. He has authored more than 30 scientific publications and patents and serves on multiple clinical and scientific advisory boards, including the Michael J. Fox Foundation for Parkinsons Research. He received his M.D. from the School of Medicine and Biomedical Sciences, SUNY at Buffalo, was a Howard Hughes Medical Institute Research Scholar at the NIH, trained in neurology at New York Hospital, Memorial Sloan Kettering, Cornell Medical Center, and did a post-doctoral fellowship in neuropharmacology at the University of Vermont.

Dr. Weiner has also been appointed to the Company’s Audit Committee, Compensation Committee, and Corporate Governance Committee. Following Dr. Weiner’s appointment to the Board and the Audit Committee, the Company has regained compliance with the independent director and audit committee requirements as set forth in Nasdaq Listing Rule 5605.

The Company is also pleased to announce that it has granted an aggregate of 235,000 stock options to consultants and a director of the Company to purchase 235,000 common shares in the capital of the Company pursuant to the Company’s share option plan. The Options are exercisable at an exercise price of $1.05 per Share for a period of five (5) years from the date of grant. The Options are subject to vesting periods over the course of the term of the Options

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.